Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York.

Intercept Pharmaceuticals, Inc.

Intercept Pharmaceuticals focuses on developing and delivering novel medicines for individuals living with rare and serious liver diseases.

Intercept Pharmaceuticals

Intercept Pharmaceuticals | 64,582 followers on LinkedIn. Our mission is to build a healthier tomorrow for patients with rare and serious liver diseases. | We are a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, including primary biliary cholangitis (PBC) and severe alcohol-associated hepatitis (sAH). 

In a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with rare and serious liver disease. We are committed to improving patients’ lives and addressing the liver community’s most pressing needs.

Janet Lewis

Chief Information Officer, at Intercept Pharmaceuticals Inc.

William Wallace

Rare Disease Therapeutic Business Specialist at Intercept Pharmaceuticals | 20+ years in the Pharmaceutical Industry | Territory Turnaround…

Grady Mateen

Director, Field Medical, Medical Science Liaison at Intercept Pharmaceuticals

Arash Thranian, PhD., MBA

Over several years, Cecilia was bounced from doctor to doctor until she found someone who finally listened to her concerns and properly diagnosed her with primary biliary cholangitis ( #PBC ). Ensuring patient voices are heard and understood is a critical aspect of healthcare, and especially important when diagnosing and managing #rarediseases . Watch Cecilia recount her experience with PBC.

We had a great time at #ACG2024 discussing the latest scientific research with the #liver community.

As we wrap up #LiverAwarenessMonth , we want to thank all those who contribute to raising awareness for #liverdisease - in October and beyond!

We’re excited to be at #ACG2024 ! Come visit us at booth #831 or at our product theater at 6:15 pm today, October 27.

Receiving a diagnosis in a rare disease like primary biliary cholangitis ( #PBC ) can take a long time, but early detection may lead to better disease management. Listen as Cecilia describes her own hunt for answers. #LiverAwarenessMonth

We were proud to support and attend the Liver Coalition of San Diego 's Liver Excellence Gala! Thank you for all that you do for the #liverdisease community. #LiverAwarenessMonth

Cecilia’s experience with primary biliary cholangitis ( #PBC ) taught her the importance of advocating for herself. Listen as she encourages others to ensure their voices are heard. #LiverAwarenessMonth

In honor of #HispanicHeritageMonth , we spoke with our very own Rosa Rodriguez about why celebrating this month is important: "Empowered Hispanic women in biotech are not just shaping the future of science - they are also forging paths for future generations, proving that innovation knows no boundaries and that diversity drives progress."

Another great year supporting the American Liver Foundation 's National Legacy Gala and gathering with those who have made an impact on the #liverdisease community! #LiverAwarenessMonth

Welcome to Intercept, Dr. Veruska Di Sena ! We're excited to have you join our team as Senior Vice President of Medical Affairs.

	Dec '13	Dec '14	Dec '15	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22
revenue	1.62M -	1.74M 7.42%	2.78M 59.70%	24.95M 796.87%	130.96M 424.85%	179.80M 37.30%	252.00M 40.15%	312.69M 24.08%	363.47M 16.24%	285.71M 21.39%
cost of revenue					1.37M -	2.52M 83.73%	4.21M 67.21%	5.32M 26.35%	3.10M 41.75%	984K 68.26%
gross profit	1.62M -	1.74M 7.42%	2.78M 59.70%	24.95M 796.87%	129.59M 419.36%	177.28M 36.81%	247.79M 39.77%	307.37M 24.04%	360.37M 17.24%	284.73M 20.99%
selling and marketing expenses		-297 -
general and administrative expenses	13.13M -	34.60M 163.49%	103.75M 199.83%	273.60M 163.72%	273.70M 0.04%	255.47M 6.66%
selling general and administrative expenses	13.13M -	34.60M 163.49%	103.75M 199.83%	273.60M 163.72%	273.70M 0.04%	255.47M 6.66%	317.42M 24.25%	332.49M 4.75%	230.85M 30.57%	176.30M 23.63%
research and development expenses	27.94M -	80.31M 187.43%	128.19M 59.62%	153.89M 20.05%	191.50M 24.44%	207.30M 8.25%	242.80M 17.12%	191.49M 21.13%	185.27M 3.24%	176.64M 4.66%
other expenses	100.38K -	776K 673.10%	2.73M 251.42%	3.90M 43.16%	4.52M 15.68%	6.77M 49.93%	8.89M 31.30%	4.41M 50.35%	2.15M 51.18%	6.52M 202.60%
cost and expenses	41.07M -	114.91M 179.77%	231.94M 101.84%	427.49M 84.31%	466.57M 9.14%	465.29M 0.27%	564.43M 21.31%	529.30M 6.22%	419.23M 20.80%	353.93M 15.58%
operating expenses	41.07M -	114.91M 179.77%	231.94M 101.84%	427.49M 84.31%	465.20M 8.82%	462.77M 0.52%	560.22M 21.06%	523.98M 6.47%	416.13M 20.58%	352.94M 15.18%
interest expense				14.20M -	29.27M 106.19%	30.52M 4.28%	41.14M 34.80%	48.05M 16.79%	54.42M 13.25%	21.39M 60.70%
ebitda	-10.90M -	57.66M 628.77%	-226.43M 492.68%	-398.63M 76.05%	-331.10M 16.94%	-278.72M 15.82%	-303.54M 8.90%	-212.20M 30.09%	-53.60M 74.74%	-61.70M 15.09%
operating income	-39.45M -	-113.17M 186.86%	-229.16M 102.49%	-402.54M 75.66%	-335.61M 16.63%	-285.49M 14.93%	-312.43M 9.44%	-216.61M 30.67%	-55.76M 74.26%	-68.22M 22.34%
depreciation and amortization	105.68K -	442.80K 318.99%	1.69M 281.89%	3.83M 126.55%	4.60M 20.10%	4.58M 0.41%	8.89M 94.02%	4.41M 50.35%	2.15M 51.18%	6.52M 202.60%
total other income expenses net	-28.34M -	-170.06M 500.04%	2.73M 101.60%	3.90M 43.16%	4.52M 15.68%	6.77M 49.93%	-32.25M 576.36%	-58.27M 80.66%	-35.67M 38.79%	-106.64M 198.99%
income before tax	-67.79M -	-283.23M 317.78%	-226.43M 20.05%	-412.83M 82.32%	-360.37M 12.71%	-309.24M 14.19%	-344.68M 11.46%	-274.88M 20.25%	-91.43M 66.74%	-174.86M 91.26%
income tax expense	28.44M -	170.39M 499.10%	1.04M 99.39%	14.27M 1,277.32%	29.19M 104.54%	6.77M 76.80%	46.37M 584.85%	49.35M 6.42%	53.60M 8.60%	-290.03M 641.14%
net income	-67.79M -	-283.23M 317.78%	-226.43M 20.05%	-412.83M 82.32%	-360.37M 12.71%	-309.24M 14.19%	-391.05M 26.46%	-324.23M 17.09%	-145.02M 55.27%	115.17M 179.42%
weighted average shs out	18.03M -	20.78M 15.28%	23.69M 14.00%	24.66M 4.09%	25.05M 1.59%	28.46M 13.61%	31.65M 11.21%	32.97M 4.16%	31.89M 3.26%	33.84M 6.09%
weighted average shs out dil	18.03M -	20.78M 15.28%	23.69M 14.00%	24.66M 4.09%	25.05M 1.59%	28.46M 13.61%	31.65M 11.21%	32.97M 4.16%	31.89M 3.26%	33.84M 6.09%
eps	-3.76 -	-13.63 262.50%	-9.56 29.86%	-16.74 75.10%	-14.38 14.10%	-10.86 24.48%	-12.35 13.72%	-9.83 20.40%	-4.55 53.71%	3.40 174.73%
epsdiluted	-3.76 -	-13.63 262.50%	-9.56 29.86%	-16.74 75.10%	-14.38 14.10%	-10.86 24.48%	-12.35 13.72%	-9.83 20.40%	-4.55 53.71%	3.40 174.73%

COM:INTERCEPTPHARMA

Intercept Pharmaceuticals

Last Close

18.96

07/11 21:00

Market Cap

794.69M

Beta: -

Volume Today

3.91M

Avg: -

Preview